Pfizer’s Business Units Enable It To Be Nimble Even as It Grows
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth integration is on track, with closing expected end of Q3 or Q4; anti-trust review is in early stages, with concern primarily about animal health overlap.
You may also be interested in...
Pfizer Watchers Try To Read New CEO's Next Moves
Pfizer, Inc.,'s abrupt management shake-up, announced Dec. 5, comes almost a year to the day its key drug Lipitor goes off patent. Whether the timing of the changes was a coincidence or the result of accumulating pressures, the patent expiration date of November 2011 is a marker for new CEO Ian Read and portends additional changes at the world's largest drug manufacturer.
Pfizer Watchers Try To Read New CEO's Next Moves
Pfizer, Inc.,'s abrupt management shake-up, announced Dec. 5, comes almost a year to the day its key drug Lipitor goes off patent. Whether the timing of the changes was a coincidence or the result of accumulating pressures, the patent expiration date of November 2011 is a marker for new CEO Ian Read and portends additional changes at the world's largest drug manufacturer.
Pfizer Turns To Insider Ian Read To See It Into Post-Lipitor Era
The 32-year Pfizer veteran will take over for Jeffrey Kindler in a succession viewed as a surprise by Wall Street.